Acute anterior uveitis (AAU) is one of the most common extra-articular manifestations of spondyloarthritis (SpA), causing a significant burden on quality of life (QoL). The GO-EASY Study provided evidence that GLM decreases the AAU occurrence rate in SpA. We aim to study the impact of GLM on the change of vision-related (VR) QoL in subjects with SpA.
Prospective multicentre observational study of SpA patients with a history of AAU treated with GLM followed-up for 12 months. We intend to recruit 30 patients, and we report herein the outcomes for the first 10 patients enrolled. The occurrence of AAU was assessed in the 2 years before GLM treatment onset and the 12 months of follow-up. The risk for a new AAU was calculated for each period. VR QoL was assessed with the self-administered NEI VFQ-25 questionnaire. Adverse events were noted.
10 patients (50% female, 70% TNFi-naive, mean age 45.8±11.1 years [range 22-65]) have completed the 12 months of follow-up. The total number of AAU flares in the 2 years preceding the start of GLM was 10, a number reduced to 1 during the 12 months of treatment. The AAU incidence rate was reduced from 1.52 to 0.10 per 100 patient-years (incidence ratio-ratio 14.79 [2.39;610.52], p<0.01). At baseline, 24 weeks and 48 weeks after GLM onset, the mean overall index NEI VFQ-25 total score was 72.4±12.0, 84.6±17.2, and 89.4±8.6, respectively. The difference across the three measurements was assessed with generalized estimating equations and was <0.001. No significant or new adverse events occurred.
The GO-VISION study is the first prospective study in the uveitis setting designed to have a patient-reported outcome measure as the primary outcome. Data from the GO-VISION study suggests that GLM is safe and effective in patients with SpA and history of AAU, reducing the AAU occurrence rate and potentially increasing VR QoL.